RU93030389A - MEANS RESTORING THE FUNCTION OF THE MESH EYE - Google Patents

MEANS RESTORING THE FUNCTION OF THE MESH EYE

Info

Publication number
RU93030389A
RU93030389A RU93030389/14A RU93030389A RU93030389A RU 93030389 A RU93030389 A RU 93030389A RU 93030389/14 A RU93030389/14 A RU 93030389/14A RU 93030389 A RU93030389 A RU 93030389A RU 93030389 A RU93030389 A RU 93030389A
Authority
RU
Russia
Prior art keywords
function
mesh eye
means restoring
restoring
eye
Prior art date
Application number
RU93030389/14A
Other languages
Russian (ru)
Other versions
RU2073518C1 (en
Inventor
В.Х. Хавинсон
С.В. Серый
А.Л. Кожемякин
Р.И. Валеев
Original Assignee
Акционерное общество закрытого типа "Неофарм"
Filing date
Publication date
Application filed by Акционерное общество закрытого типа "Неофарм" filed Critical Акционерное общество закрытого типа "Неофарм"
Priority to RU93030389A priority Critical patent/RU2073518C1/en
Priority claimed from RU93030389A external-priority patent/RU2073518C1/en
Priority to PCT/IB1994/000192 priority patent/WO1995000156A1/en
Priority to AU69795/94A priority patent/AU6979594A/en
Publication of RU93030389A publication Critical patent/RU93030389A/en
Application granted granted Critical
Publication of RU2073518C1 publication Critical patent/RU2073518C1/en

Links

Claims (1)

Средство относится к медицине, в частности к фармакологии. Изобретение обеспечивает разработку и применение лекарственного пептидного препарата "Ретилин", который используют в качестве средства для лечения и предупреждения заболеваний и патологических состояний, сопровождающихся нарушением функции сетчатки глаза.The tool relates to medicine, in particular to pharmacology. The invention provides for the development and use of the medicinal peptide drug "Retilin", which is used as a means for treating and preventing diseases and pathological conditions involving impaired retinal function.
RU93030389A 1993-06-17 1993-06-17 Agent recovering retina eye function RU2073518C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU93030389A RU2073518C1 (en) 1993-06-17 1993-06-17 Agent recovering retina eye function
PCT/IB1994/000192 WO1995000156A1 (en) 1993-06-17 1994-06-17 Compositions and methods for treatment and prevention of retinal dysfunctions
AU69795/94A AU6979594A (en) 1993-06-17 1994-06-17 Compositions and methods for treatment and prevention of retinal dysfunctions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93030389A RU2073518C1 (en) 1993-06-17 1993-06-17 Agent recovering retina eye function

Publications (2)

Publication Number Publication Date
RU93030389A true RU93030389A (en) 1995-06-27
RU2073518C1 RU2073518C1 (en) 1997-02-20

Family

ID=20142934

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93030389A RU2073518C1 (en) 1993-06-17 1993-06-17 Agent recovering retina eye function

Country Status (3)

Country Link
AU (1) AU6979594A (en)
RU (1) RU2073518C1 (en)
WO (1) WO1995000156A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA3148917A1 (en) * 2006-03-08 2007-09-13 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
RU2301072C1 (en) * 2006-06-22 2007-06-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Agent for normalizing of blood-vessel function and method for production thereof
RU2558976C2 (en) * 2013-09-19 2015-08-10 Венера Айратовна Шаимова Method of predicting development of vitreoretinal traction in case of peripheral retinal degeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117057C3 (en) * 1971-04-07 1980-07-31 Biofarm Fabrica De Medicamente, Bukarest (Rumaenien) Process for the manufacture of a medicament for the treatment of eye diseases
IT1219839B (en) * 1988-02-08 1990-05-24 Fidia Farmaceutici PURIFICATION, CHARACTERIZATION AND APPLICATION OF A NEURONOTROPHIC FACTOR DERIVED FROM NAMMIFEROUS BRAIN
IT1219874B (en) * 1988-03-18 1990-05-24 Fidia Farmaceutici USE OF THE HUMAN NERVE GROWTH FACTOR AND ITS PHARMACEUTICAL COMPOSITIONS
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor

Similar Documents

Publication Publication Date Title
ATE241365T1 (en) PREPARATIONS CONTAINING SACCHARIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
KR960700742A (en) ATOPIC DISEASE REMEDY
ATE293417T1 (en) SCLEROTIC PROSTHESIS FOR THE TREATMENT OF PRESBIOUS SIGHT AND OTHER EYE DISEASES
CA2041260A1 (en) Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
PT668763E (en) USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE
RU94002133A (en) 6-CHLOR-5-FTOR-3- (2-TENOIL) -2-OXINDOL-1-CARBOXAMIDE AS AN ANALOGESIC AND ANIMATERATIVE MEDICATION
EP1538163A3 (en) Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease
RU93030389A (en) MEANS RESTORING THE FUNCTION OF THE MESH EYE
DE69618560D1 (en) MEDICINE AGAINST OPHTHALMIC DISEASES
DE69007065D1 (en) Use of diadenosine 5 ', 5' '' - p1, p4-tetraphosphate for the manufacture of a medicament for the treatment of heart diseases.
FI942400A0 (en) Drug against nerve diseases
IT9020968A0 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES
CA2167257A1 (en) Use of Sertraline to Treat Cancer Patients
EP0373771A3 (en) New pharmaceutical uses for cystatins
BR9406865A (en) Use of a pharmaceutically acceptable salt of ropivacaine in the manufacture of a pharmaceutical process for the treatment of a person in need of pain relief and pharmaceutical preparation
BR9809457A (en) Bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy.
DE69739190D1 (en) MEDICAMENT FOR THE TREATMENT OF OCULAR CRUSH DISEASES
FR2644060B1 (en) MEDICINE, ESPECIALLY FOR THE TREATMENT OF CUTANEOUS, EYE AND GENITAL HERPES VIRUS DISEASES
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
HUP0004647A2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
DE69421705T2 (en) Use of Efaroxan and its derivatives for the manufacture of a medicament for the treatment of neurogenerative diseases
FI953725A0 (en) Use of ornithine aminotransferase inhibitors in the manufacture of a medicament for the treatment of Alzheimer's disease